Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Forrester Research Q1 Profit Rises

RELATED NEWS
Trade FORR now with 

Forrester Research Inc. (FORR: Quote) reported first-quarter net income of $3.2 million or $0.14 per share, up from $2.9 million or $0.13 per share last year.

Excluding items, pro forma net income was $5.1 million or $0.22 per share, compared to $4.8 million or $0.21 per share a year ago.

On average, 4 analysts polled by Thomson Reuters expected earnings of $0.18 per share for the quarter. Analysts' estimates typically exclude special items.

Revenues for the quarter rose to $70.3 million from $65.7 million a year ago.

Analysts expected revenues of $70.27 million for the quarter. Looking ahead, the company expects earnings of $0.94-$1.00 per share and revenues of $308.0 million-$316.0 million for the full year 2012.

Analysts currently expect earnings of $1.20 per share and revenues of $311.78 million for the full year 2012 .

The company noted that its board of directors has approved a quarterly dividend of $0.14 per share payable June 20 to shareholders of record on June 6.

Click here to receive FREE breaking news email alerts for Forrester Research Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Proctor and Gamble (PG) has sold two of its soap brands to European consumer products giant Unilever (UN). Cincinnati-based P&G says the sale includes the global Camay brand, the Zest brand outside of North America and its Talisman manufacturing plant in Mexico. The plant employs approximately... Dish Network is no longer carrying Fox News in yet another dispute for the television provider. Fox News, which changed the face of cable news with its ardent advocacy of conservative issues, went dark Sunday, replaced on Dish by The Blaze, Glen Beck's new right-leaning channel. Fox Business channel... Swiss drug maker Roche Holding said a late-stage trial of its breast cancer drug Kadcyla did not provide superior results compared with an existing therapy.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.